Remus Pharmaceuticals Seeks Shareholder Approval for Main Board Migration
Remus Pharmaceuticals Ltd · Annual General Meeting · 05 Sept 2026, 7:40 pm
Remus Pharmaceuticals Seeks Shareholder Approval for Main Board Migration Remus Pharmaceuticals Limited issued a Postal Ballot Notice seeking shareholder approval via special resolution to migrate its equity shares (face value ₹10.00) from the NSE Emerge platform to the Main Boards of NSE and BSE. The cut-off date for voting eligibility is 28th Aug'26. Remote e-voting runs from 7th Sep'26 to 6th Oct'26, with results announced on or before 8th Oct'26. The migration aims to enhance liquidity, visibility, and broader investor participation, subject to statutory approvals and non-promoter voting thresholds per SEBI ICDR regulations.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript · 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording · 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation · 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. · 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet · 29 Oct 2026
